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Abstract
Myotilinopathies are a group of muscle disorders caused by mutations in the MYOT gene. It was first
described in two families suffering from limb girdle muscle dystrophy type 1 (LGMD 1A), and later
identified in a subset of dominant or sporadic patients suffering from myofibrillar myopathy, as well
as in a family with spheroid body myopathy. Disease phenotypes associated with MYOT mutations
are clinically heterogeneous and include pure LGMD forms as well as late-onset distal myopathies.
We report here on a 53-year-old male suffering from a unique clinical profile characterized by
generalized symmetrical increase in muscle bulk leading to a Herculean appearance. Muscle
weakness and stiffness in the lower extremities were the patient’s main complaints. Muscle MRI
showed extensive fatty infiltration in the thigh and leg muscles and a muscle biopsy showed a
myofibrillar myopathy with prominent protein aggregates. Gene sequencing revealed a Ser55Phe
missense mutation in the myotilin gene. The mutation was identified in his older brother, who
presented a mild hypertrophic appearance and had a myopathic pattern in EMG, despite not
presenting any of the complaints of the proband and having normal muscle strength. This finding,
and his deceased father and paternal aunt’s similar gait disorders, suggest that this is in fact a new
autosomal dominant kindred. The present observations further expand the spectrum of clinical
manifestations associated with mutations in the myotilin gene.
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1. Introduction
Myotilin is a 57-kDa component of sarcomeric Z-discs exclusively expressed in skeletal and
cardiac muscle [1]. Myotilin interacts with several other Z-disc proteins including alpha-
actinin, filamin C, F-actin and FATZ. These interactions play a major role in the dynamic
molecular events mediating myofibrillar assembly in normal and diseased skeletal muscle
[1–4]. Myotilin is encoded by a single gene on chromosome 5q31 [1,5]. The coding sequence
encompasses 10 exons and codes for 498 amino acids. Seven missense mutations in the
MYOT gene are currently known [6–10]. They are all clustered in exon 2, a region which has
been shown to be a hot spot for mutations. A wide spectrum of clinical manifestations
associated with myotilin mutations has been reported. These include autosomal dominant
LGMD syndromes in combination with dysarthria (LGMD 1A) [6,7,11], and late onset
sporadic or dominant distal myopathies [8,9,12–14]. Muscle biopsies performed in these latter
cases have demonstrated a myofibrillar myopathy [8,9]. Still other cases may present with
mixed proximal and distal phenotypes [8,9,14]. Cardiomyopathy, respiratory insufficiency,
and peripheral neuropathy may occasionally be additional features in patients [8,9]. Muscle
atrophy has been described in some cases [9,12,13]; however, generalized muscle pseudo-
hypertrophy has been never observed in myotilinopathy. Here we report on a 53-year-old
patient presenting with a distinct clinical phenotype characterized by generalized muscle
pseudo-hypertrophy, stiffness and mild muscle weakness due to a myotilin mutation.
2. Case report
A 53-year-old man was referred to our Neuromuscular Unit for evaluation of slowly
progressive gait difficulty over the previous 12 years. Two years before admission, the patient
noticed progressive muscular weakness in the lower limbs, and to a lesser extent in the upper
extremities, as well as muscle pain and stiffness when walking. He was unable to walk for
more than 20m without resting, mimicking intermittent claudication syndrome. He also had
severe difficulties in climbing and descending stairs, rising from a chair and getting in and out
of vehicles. The patient had never done sports or bodybuilding and had never taken hormones
or anabolic drugs.
Physical examination revealed a patient with a Herculean appearance with a symmetrical
increase in muscle bulk involving the neck, trunk and extremities (Fig. 1). He could not stand
with his feet together and the distance between the medial malleoli necessary to stand without
falling was 32 cm. He was able to walk without support but with considerable staggering, and
had difficulties in half-turning. When walking, the trunk was slightly flexed forwards and the
speed was markedly reduced. The muscles felt stiff on palpation. There was no
clinicalmyotonia or muscular edema. Ankle jerks were absent. Bilateral Achilles tendon
retraction and incipient elbow retraction were also evident. There was no facial weakness,
dysarthria or macroglossia. Livedo reticularis was observed as most marked in the lower limbs.
Muscle strength (MRC scale) was 4/5 in the deltoids, biceps brachialis and pectoralis muscles;
4+/5 in the neck flexor–extensors, wrist and finger extensor and interosseous muscles; 5/5 in
the triceps, wrist flexors, and finger flexors. In the lower limbs, muscle strength was 4/5 in the
gluteus maximus, iliopsoas, tibialis anterior, peroneal and toe extensor muscles, 4+/5 in the
quadriceps, and 5/5 in the hip adductor and plantar flexor muscles.
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Sensory and motor nerve conduction studies were normal. EMG examination showed a
myopathic pattern with spontaneous activity at rest with positive sharp waves, fibrillation
potentials and complex repetitive discharges with a diffuse distribution but which was most
marked in the vastus medialis, tibialis anterior, deltoids and extensor digitorum communis. CK
levels were within normal levels. Thyroid function was normal. No anticardiolipin antibodies
were present. No monoclonal gammapathy was detected. The electrocardiogram showed non-
specific abnormalities consisting of asymmetric T-waves in aVL, V5 and V6. Echocardiogram,
brain and spinal MRI were normal.
A brother of the index case, aged 55, had suffered an acute myocardial infarction at 52 years
of age. Despite presenting a similar Herculean appearance to his brother, although to a lesser
extent (160 cm tall, weight 80 kg, neck perimeter 45 cm, thigh muscles 50 cm, calf muscles
46 cm), the examination showed normal muscle strength and normal CK levels. Nerve
conduction studies were normal, and electromyography of the deltoid, vastus medialis, rectus
femoris and tibialis anterior muscles showed a myopathic pattern, but no complex repetitive
discharges. The patient’s healthy 75-year-old mother had no signs of neuromuscular disease.
However, the patient’s father, who had died from Alzheimer’s disease at 71 years old, presented
a gait disorder similar to the proband, as did a paternal aunt, about whom we only know that
she had an EMG examination consistent with a myopathy.
3. Methods
3.1. Muscle MRI
Magnetic resonance imaging was performed on a 1.5 T whole body MRI system (Magnetom
Vision, Siemens Medical Solutions) using the standard body coil including an axial T1-
weighted MRI image (TR 483, TE 12) and a STIR MRI image (TR 5000, TE 29).
3.2. Muscle biopsy
An open muscle biopsy was obtained from the vastus lateralis of the patient’s right thigh, with
severe fat infiltration observed. Suture of the fascia lata was difficult due to the tension in the
pseudo-hypertrophic thigh muscles. The sample was processed according to the methods
described elsewhere [9]. Filamin C immunohistochemistry using the monoclonal anti-filamin
C antibody RR90 was also performed [15].
3.3. Molecular genetic analysis
Informed consent for genetic analysis was obtained from the proband and his brother. Genomic
DNA was obtained from peripheral leukocytes and analyzed for myotilin mutation using the
primers and conditions described elsewhere [9].
4. Results
4.1. Muscle MRI
MRI showed severe fatty infiltration involving the vastus intermedius, vastus medialis,
adductor magnus, semimembranosus, biceps femoris, and to a lesser extent, the vastus lateralis.
The rectus femoris, gracilis, semitendinosus, and sartorius muscles were preserved but
contained minor areas of fatty infiltration. At mid-leg level, fatty infiltration was observed on
the anterior tibialis, lateral gastrocnemious, and to a lesser extent, the medial gastrocnemious.
The remaining muscle groups of the leg, including the soleus muscles, were well-preserved or
showed minor abnormalities. This fatty infiltration was also pseudo-hypertrophic, leading to
a bilateral symmetric increase in the volume of the thighs and legs (Fig. 2).
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A muscle biopsy taken from the vastus lateralis revealed a marked variation in the fiber size,
with some atrophic fibers of both histochemical types often clustered in small groups,
intermediate-size fibers and several large round fibers. There were increased numbers of
internal nuclei, endomysial fibrosis, and areas replaced by fatty tissue. Muscle fiber necrosis
and phagocytosis were occasionally seen. No inflammatory infiltrates were observed. Large
numbers of fibers containing vacuoles were seen, most of which were unrimmed. A large
number of fibers contained prominent polymorphous hyaline inclusions which stained dark-
blue to purple with the modified trichrome stain, and were eosinophilic on hematoxylin and
eosin staining, with some displaying strong congophilia. No congophilic material was observed
around the intramuscular vessels or in the endomysium. Small cytoplasmic bodies were also
present in many fibers. Oxidative and ATPase activity was reduced in the fiber areas occupied
by the inclusions. There was type I fiber predominance.
Immunohistochemical studies revealed prominent myotilin, desmin, filamin C, dystrophin and
ubiquitin immunoreactivity (Fig. 3). EM examination showed areas of major myofibrillar
abnormalities that included electrondense material of Z-disc origin as well as fine granular and
filamentous material. In addition, autophagic vacuoles, clusters of mitochondria and some
residual polymorphic bodies were observed (Fig. 3).
4.3. Molecular genetic analysis
Sequence analysis identified a c.444C>T missense mutation in exon 2 of the myotilin gene,
predicted to result in a change of residue 55 from serine to phenylalanine (Ser55Phe). The same
mutation was found in the patient’s brother. No irregularities in this region were found on
sequencing 100 Spanish control individuals.
5. Discussion
We have described a patient suffering from generalized muscle pseudo-hypertrophy and
stiffness caused by a mutation in the myotilin gene. The genealogical background suggests an
autosomal dominant transmission as previously reported in kindreds with the Ser55Phe MYOT
mutation.
Although the case seems sporadic in nature, the presence of an asymptomatic brother who
nevertheless carried the mutation and who to date remains asymptomatic, with only a
pathological EMG, as well as the gait disorders in the proband’s deceased father and paternal
aunt, suggest otherwise. This clinical intra-familial heterogeneity has previously been reported
in myotilinopathy pedigrees. Investigation of the previous three generations on both sides of
the family also shows that there is no consanguinity. Furthermore, possible consanguinity was
deemed extremely unlikely, considering that the mother and father came from villages 700
kilometers apart in rural Spain in the 1940s.
The family insisted after repeated questioning that the father did not have a hypertrophic build,
although no conclusive full body photographs of him were available. There is a theoretical
possibility that there are two pathological processes at work — a myotilin defect and
pseudohypertrophy. However, this has yet to be ascertained.
Myotilinopathy was originally described in two families suffering from LGMD 1A [6,7].
Affected patients in both families presented between the ages of 18 and 58 with proximal
weakness in the lower extremities, which later spread to involve the distalmuscles. Dysarthria
was a prominent symptomin somecases. Amuscle biopsy performed in one affected member
showed variation in fiber size, fiber splitting, a large number of rimmed vacuoles and patches
of Z-line streaming [6,7,11]. No immunocytochemical studies were performed. More recently,
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mutations in myotilin gene were found in a subset of patients suffering from myofibrillar
myopathy [8,9]. In these later cases, the age of onset of the disease varied between 42 and 77
years old; distal weakness in the lower extremities is the most common mode of presentation,
although some cases it may present with proximal weakness, or with mixed proximal and distal
weakness [8,9]. The Ser55Phe myotilin mutation identified in the patient described here was
previously found in a LGMD1A family [7] as well as in several sporadic or familial cases
presenting with a late-onset distal myopathy [8,9,12,13], and in two sporadic cases presenting
with late-onset proximal weakness [9]. Cardiopathy was absent except for a single case [9].
Three additional myotilin mutations (S60C, S60F and S91I) have been found in patients
presenting with progressive muscle weakness in either the proximal or the distal muscles, with
decreased reflexes in the legs and various degrees of cardiac involvement [8,9,14]. Finally, an
S39F MYOT mutation has been shown to be the cause of spheroid body myopathy, a disorder
which has clinical and pathological features overlapping with LGMD 1A and MFM [11,16].
Irrespective of the mode of presentation, muscle weakness in myotilinopathy may be
accompanied by muscle atrophy alone or in combination with stiffness and myalgia in some
patients [8,9,12–14]. Painful enlargement of leg muscles has been observed in some cases;
however, generalized muscle pseudo-hypertrophy has never been described in myotilinopathy.
Muscle MRI performed on our patient showed severe fatty infiltration of several muscle groups
in the thigh and leg, thus indicating that the increase in muscle bulk was a result of fatty
replacement rather than a true muscle hypertrophy. The pattern of muscle involvement
observed in the thigh muscles of the patient reported here mirrors the abnormalities previously
found in several other myotilinopathy cases [8,12–13]. However, unlike previously published
cases, the soleus muscle, which has been shown to be the first muscle involved in
myotilinopathy, was well preserved. Interestingly, this preservation of the soleus muscles
present in our patient was described in transgenic mice expressing the myotilin T57I mutation
[19]. The reasons behind this sparing are not yet fully known.
In summary, we have described generalized muscle pseudo-hypertrophy and stiffness as a
novel phenotypic manifestation of myotilinopathy. Generalized muscle pseudo-hypertrophy
as seen in our case may be observed in other clinical conditions such as hypothyroid myopathy
and amyloid myopathy [17,18]. Myotilinopathy should be therefore considered in the
differential diagnosis of patients presenting with generalized muscle pseudo-hypertrophy.
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Rear and side view of the patient showing generalized skeletal muscle enlargement and pseudo-
hypertrophy.
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MRI at the pelvis (A), mid-thigh (B), and mid-leg level (C) showing severe fatty replacement
of the glutei, vastus intermedius, vastus medialis, adductor magnus, semimembranosus, and
biceps femoris, and less severe changes in the vastus lateralis. The rectus femoris, gracilis,
sartorius and semi-tendinosus are well preserved. At mid-leg level, fatty infiltration is observed
in the lateral gastrocnemius, medial gastrocnemius and anterior tibialis. The soleus muscle is
well preserved. The fatty infiltration causes a bilateral symmetrical increase in the volume of
limbs (arrowed).
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Muscle biopsy showing a wide variation in the fiber size, central nuclei and mild endomysial
fibrosis. Several muscle fibers contain cytoplasmic inclusions, which stain pink on hematoxylin
and eosin (A), and dark purple with the modified trichrome stain (B). Some of the fibers contain
rimmed and unrimmed vacuoles (A). The inclusions show strong myotilin (C) and filamin C
(D) immunoreactivity. Under EM, large areas of sarcomeric disorganization are replaced by
electrondense material of Z-disc origin, remnants of filaments and fine granular material (E
and F). A cluster of mitochondria is seen in F. A ×200; B ×600; C and D ×400. Bar in E and
F=1 μm.
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